<ul>
<li>華爾街看好的 3 只市值低於 20 美元的中盤股</li>
</ul>
<p>Ardelyx, Inc. (NASDAQ:ARDX - 免費報告) - HC Wainwright 的股票研究分析師在 7 月 3 日星期三發佈的研究報告中上調了他們對 Ardelyx 2026 財年每股收益的預測。HC Wainwright 分析師 E. Arce 現預計，這家生物製藥公司將在今年實現每股收益 0.68 美元，高於他們之前的預測 0.58 美元。Ardelyx 當前全年每股收益的共識預測為（0.36）美元。HC Wainwright 還預測 Ardelyx 2027 財年每股收益為 1.41 美元，2028 財年每股收益為 1.65 美元。</p>
<p>Ardelyx (NASDAQ:ARDX - 獲取免費報告) 於 5 月 2 日星期四公佈了其季度財報。這家生物製藥公司報告該季度每股收益（EPS）為（0.11）美元，超過了（0.13）的共識預測 0.02 美元。該季度公司營收為 4,600 萬美元，而分析師預測為 3,640 萬美元。Ardelyx 淨利潤率為-41.36%，淨資產收益率為-41.65%。公司季度營收同比增長 303.5%。去年同期，公司每股收益為（0.13）美元。</p>
<ul>
<li>2022 年初滑落後，Ardelyx 是否值得買入</li>
</ul>
<p>ARDX 成為其他幾家研究機構關注的對象。Piper Sandler 將 Ardelyx 的評級從 “增持” 調降至 “中性”，並將公司的價格目標從 15.00 美元下調至 7.00 美元，日期為 7 月 2 日星期二。Leerink Partners 在 4 月 5 日星期五重申了對 Ardelyx 的 “表現優異” 評級。StockNews.com 在 6 月 28 日星期五的研究報告中將 Ardelyx 的評級從 “持有” 調降至 “賣出”。SVB Leerink 在 4 月 5 日星期五的研究報告中開始對 Ardelyx 進行覆蓋。他們給出了一個 “表現優異” 的評級和 14.00 美元的價格目標。最後，Cantor Fitzgerald 在 6 月 20 日星期四的研究報告中重申了對 Ardelyx 的 “增持” 評級。一位分析師給予該股票賣出評級，一位持有評級，七位買入評級，一位強烈買入評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “中度買入”，平均目標價為 11.31 美元。</p>
<p><strong>查看我們關於 ARDX 的最新報告</strong></p>
<h2>Ardelyx 股票表現</h2>
<p>週一，納斯達克 ARDX 開盤價為 5.29 美元。Ardelyx 的 12 個月最低價為 3.16 美元，最高價為 10.13 美元。公司的速動比率為 4.36，流動比率為 4.53，資產負債比為 0.66。股票市值為 12.3 億美元，市盈率為-18.89，貝塔係數為 0.83。公司的 50 天簡單移動平均線為 6.93 美元，200 天簡單移動平均線為 7.61 美元。</p>
<h2>對 Ardelyx 的對沖基金看法</h2>
<p>近期大型投資者已調整了他們對該公司的持股。HighMark Wealth Management LLC 在第一季度收購了 Ardelyx 的新股份，價值約 36,000 美元。Newbridge Financial Services Group Inc.在第一季度購入了 Ardelyx 的新頭寸，價值約 64,000 美元。SJS Investment Consulting Inc.在第四季度購入了 Ardelyx 的新頭寸，價值 62,000 美元。Jump Financial LLC 在第四季度收購了 Ardelyx 的新股份，價值 63,000 美元。最後，Paloma Partners Management Co 在第一季度購入了 Ardelyx 的新頭寸，價值 86,000 美元。機構投資者擁有公司股份的 58.92%。</p>
<h2>內部人員的買賣行為</h2>
<p>在其他 Ardelyx 新聞中，內部人員 David P. Rosenbaum 於 6 月 3 日星期一以 7.00 美元的平均價格出售了公司股票的 17,872 股。交易完成後，該內部人員現直接持有公司股票 158,502 股，價值約 1,109,514 美元。該交易已在美國證券交易委員會的法律文件中披露，可通過此鏈接獲得。另外，內部人員 Robert Blanks 於 6 月 21 日星期五以 5.96 美元的平均價格出售了公司股票 38,000 股。交易完成後，該內部人員現持有公司 324,331 股，價值 1,933,012.76 美元。該交易已在證券交易委員會的文件中披露，可通過此鏈接訪問。此外，內部人員 David P. Rosenbaum 於 6 月 3 日星期一以 7.00 美元的平均價格出售了公司股票 17,872 股。股票總價值為 125,104.00 美元。交易完成後，該內部人員現持有公司股票 158,502 股，價值 1,109,514 美元。關於此次交易的披露可在此處找到。內部人員在過去 90 天內已出售了價值 4,117,225 美元的公司股票 534,119 股。公司股份的 5.50% 歸公司內部人員所有。</p>
<h2>關於 Ardelyx（獲取免費報告）</h2>
<p>Ardelyx, Inc.是一家生物製藥公司，致力於在美國和國際市場上發現、開發和銷售治療胃腸和心臟腎臟疾病的藥物。該公司的主要產品候選藥物是 tenapanor，用於治療具有便秘型腸易激綜合徵的患者。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們喜歡的五隻比 Ardelyx 更好的股票</li>
<li>內部人員賣出解釋：能否指導您的投資選擇？</li>
<li>MarketBeat 周評 - 7/1 - 7/5</li>
<li>投資中降級意味着什麼？</li>
<li>Constellation Brands 股票 2025 年第一季度：擊敗安海斯 - 布什？</li>
<li>複利利息如何計算？</li>
<li>高通股票在負面消息面前持續上漲</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJEWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJEWA"/></p>
<p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快速和最準確的報道。在發佈之前，該故事已經經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 奧巴馬贏得總統辯論（來自 Porter &amp; Company）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjAw"/></p>
<h2>現在是否值得投資$1,000 在 Ardelyx？</h2>
<p>在考慮 Ardelyx 之前，您可能想要聽聽這個。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在購買的股票...而 Ardelyx 不在名單上。</p>
<p>雖然 Ardelyx 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

ARDX

<p>HC Wainwright 已經提高了對 Ardelyx, Inc. (NASDAQ:ARDX) 2026 財年每股收益的預測。這家生物製藥公司預計全年每股收益為$0.68，高於之前的預測$0.58。Ardelyx 目前的全年盈利共識預測為每股 ($0.36)。HC Wainwright 還發布了 2027 財年每股收益為$1.41 和 2028 財年每股收益為$1.65 的預測。該公司的股價週一開盤價為$5.29</p>

<ul>
<li>3 mid-caps under $20 that Wall Street loves</li>
</ul>
<div class="lb-trans"><ul>
<li>華爾街看好的 3 只市值低於 20 美元的中盤股</li>
</ul>
</div><p>Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Equities research analysts at HC Wainwright upped their FY2026 earnings per share estimates for Ardelyx in a research note issued on Wednesday, July 3rd. HC Wainwright analyst E. Arce now anticipates that the biopharmaceutical company will post earnings per share of $0.68 for the year, up from their previous forecast of $0.58. The consensus estimate for Ardelyx's current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Ardelyx's FY2027 earnings at $1.41 EPS and FY2028 earnings at $1.65 EPS.</p>
<div class="lb-trans"><p>Ardelyx, Inc. (NASDAQ:ARDX - 免費報告) - HC Wainwright 的股票研究分析師在 7 月 3 日星期三發佈的研究報告中上調了他們對 Ardelyx 2026 財年每股收益的預測。HC Wainwright 分析師 E. Arce 現預計，這家生物製藥公司將在今年實現每股收益 0.68 美元，高於他們之前的預測 0.58 美元。Ardelyx 當前全年每股收益的共識預測為（0.36）美元。HC Wainwright 還預測 Ardelyx 2027 財年每股收益為 1.41 美元，2028 財年每股收益為 1.65 美元。</p>
</div><p>Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. The company had revenue of $46.00 million for the quarter, compared to analyst estimates of $36.40 million. Ardelyx had a negative net margin of 41.36% and a negative return on equity of 41.65%. The business's quarterly revenue was up 303.5% on a year-over-year basis. During the same period last year, the business posted ($0.13) EPS.</p>
<ul>
<li>Is Ardelyx is A Buy After Slip in Early 2022</li>
</ul>
<div class="lb-trans"><p>Ardelyx (NASDAQ:ARDX - 獲取免費報告) 於 5 月 2 日星期四公佈了其季度財報。這家生物製藥公司報告該季度每股收益（EPS）為（0.11）美元，超過了（0.13）的共識預測 0.02 美元。該季度公司營收為 4,600 萬美元，而分析師預測為 3,640 萬美元。Ardelyx 淨利潤率為-41.36%，淨資產收益率為-41.65%。公司季度營收同比增長 303.5%。去年同期，公司每股收益為（0.13）美元。</p>
<ul>
<li>2022 年初滑落後，Ardelyx 是否值得買入</li>
</ul>
</div><p>ARDX has been the subject of several other research reports. Piper Sandler downgraded Ardelyx from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and cut their price objective for the company from $15.00 to $7.00 in a research report on Tuesday, July 2nd. Leerink Partnrs reaffirmed an &#34;outperform&#34; rating on shares of Ardelyx in a report on Friday, April 5th. StockNews.com cut Ardelyx from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Friday, June 28th. SVB Leerink initiated coverage on Ardelyx in a research report on Friday, April 5th. They issued an &#34;outperform&#34; rating and a $14.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating on shares of Ardelyx in a research note on Thursday, June 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $11.31.</p>
<div class="lb-trans"><p>ARDX 成為其他幾家研究機構關注的對象。Piper Sandler 將 Ardelyx 的評級從 “增持” 調降至 “中性”，並將公司的價格目標從 15.00 美元下調至 7.00 美元，日期為 7 月 2 日星期二。Leerink Partners 在 4 月 5 日星期五重申了對 Ardelyx 的 “表現優異” 評級。StockNews.com 在 6 月 28 日星期五的研究報告中將 Ardelyx 的評級從 “持有” 調降至 “賣出”。SVB Leerink 在 4 月 5 日星期五的研究報告中開始對 Ardelyx 進行覆蓋。他們給出了一個 “表現優異” 的評級和 14.00 美元的價格目標。最後，Cantor Fitzgerald 在 6 月 20 日星期四的研究報告中重申了對 Ardelyx 的 “增持” 評級。一位分析師給予該股票賣出評級，一位持有評級，七位買入評級，一位強烈買入評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “中度買入”，平均目標價為 11.31 美元。</p>
</div><p><strong>Check Out Our Latest Report on ARDX</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 ARDX 的最新報告</strong></p>
</div><h2>Ardelyx Stock Performance</h2>
<div class="lb-trans"><h2>Ardelyx 股票表現</h2>
</div><p>NASDAQ ARDX opened at $5.29 on Monday. Ardelyx has a twelve month low of $3.16 and a twelve month high of $10.13. The company has a quick ratio of 4.36, a current ratio of 4.53 and a debt-to-equity ratio of 0.66. The stock has a market cap of $1.23 billion, a P/E ratio of -18.89 and a beta of 0.83. The company's 50-day simple moving average is $6.93 and its 200 day simple moving average is $7.61.</p>
<div class="lb-trans"><p>週一，納斯達克 ARDX 開盤價為 5.29 美元。Ardelyx 的 12 個月最低價為 3.16 美元，最高價為 10.13 美元。公司的速動比率為 4.36，流動比率為 4.53，資產負債比為 0.66。股票市值為 12.3 億美元，市盈率為-18.89，貝塔係數為 0.83。公司的 50 天簡單移動平均線為 6.93 美元，200 天簡單移動平均線為 7.61 美元。</p>
</div><h2>Hedge Funds Weigh In On Ardelyx</h2>
<div class="lb-trans"><h2>對 Ardelyx 的對沖基金看法</h2>
</div><p>Large investors have recently modified their holdings of the business. HighMark Wealth Management LLC acquired a new stake in Ardelyx during the first quarter worth approximately $36,000. Newbridge Financial Services Group Inc. bought a new position in Ardelyx in the first quarter worth approximately $64,000. SJS Investment Consulting Inc. bought a new position in shares of Ardelyx in the 4th quarter worth $62,000. Jump Financial LLC acquired a new stake in Ardelyx in the 4th quarter valued at $63,000. Finally, Paloma Partners Management Co acquired a new position in Ardelyx during the first quarter worth $86,000. Institutional investors own 58.92% of the company's stock.</p>
<div class="lb-trans"><p>近期大型投資者已調整了他們對該公司的持股。HighMark Wealth Management LLC 在第一季度收購了 Ardelyx 的新股份，價值約 36,000 美元。Newbridge Financial Services Group Inc.在第一季度購入了 Ardelyx 的新頭寸，價值約 64,000 美元。SJS Investment Consulting Inc.在第四季度購入了 Ardelyx 的新頭寸，價值 62,000 美元。Jump Financial LLC 在第四季度收購了 Ardelyx 的新股份，價值 63,000 美元。最後，Paloma Partners Management Co 在第一季度購入了 Ardelyx 的新頭寸，價值 86,000 美元。機構投資者擁有公司股份的 58.92%。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人員的買賣行為</h2>
</div><p>In other Ardelyx news, insider David P. Rosenbaum sold 17,872 shares of the firm's stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $7.00, for a total value of $125,104.00. Following the transaction, the insider now directly owns 158,502 shares of the company's stock, valued at approximately $1,109,514. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Ardelyx news, insider Robert Blanks sold 38,000 shares of the firm's stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $5.96, for a total value of $226,480.00. Following the sale, the insider now owns 324,331 shares in the company, valued at $1,933,012.76. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, insider David P. Rosenbaum sold 17,872 shares of the company's stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $7.00, for a total transaction of $125,104.00. Following the transaction, the insider now owns 158,502 shares of the company's stock, valued at $1,109,514. The disclosure for this sale can be found here. Insiders have sold 534,119 shares of company stock valued at $4,117,225 over the last 90 days. 5.50% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Ardelyx 新聞中，內部人員 David P. Rosenbaum 於 6 月 3 日星期一以 7.00 美元的平均價格出售了公司股票的 17,872 股。交易完成後，該內部人員現直接持有公司股票 158,502 股，價值約 1,109,514 美元。該交易已在美國證券交易委員會的法律文件中披露，可通過此鏈接獲得。另外，內部人員 Robert Blanks 於 6 月 21 日星期五以 5.96 美元的平均價格出售了公司股票 38,000 股。交易完成後，該內部人員現持有公司 324,331 股，價值 1,933,012.76 美元。該交易已在證券交易委員會的文件中披露，可通過此鏈接訪問。此外，內部人員 David P. Rosenbaum 於 6 月 3 日星期一以 7.00 美元的平均價格出售了公司股票 17,872 股。股票總價值為 125,104.00 美元。交易完成後，該內部人員現持有公司股票 158,502 股，價值 1,109,514 美元。關於此次交易的披露可在此處找到。內部人員在過去 90 天內已出售了價值 4,117,225 美元的公司股票 534,119 股。公司股份的 5.50% 歸公司內部人員所有。</p>
</div><h2>About Ardelyx (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 Ardelyx（獲取免費報告）</h2>
</div><p>Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.</p>
<div class="lb-trans"><p>Ardelyx, Inc.是一家生物製藥公司，致力於在美國和國際市場上發現、開發和銷售治療胃腸和心臟腎臟疾病的藥物。該公司的主要產品候選藥物是 tenapanor，用於治療具有便秘型腸易激綜合徵的患者。</p>
</div><h2>Read More</h2>
<ul>
<li>Five stocks we like better than Ardelyx</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>MarketBeat Week in Review – 7/1 - 7/5</li>
<li>What Does Downgrade Mean in Investing?</li>
<li>Constellation Brands Stock Q1 2025: Crushing Anheuser-Busch?</li>
<li>How is Compound Interest Calculated?</li>
<li>Qualcomm Stock Continues to Rise in the Face of Negative News</li>
</ul>
<div class="lb-trans"><h2>閲讀更多</h2>
<ul>
<li>我們喜歡的五隻比 Ardelyx 更好的股票</li>
<li>內部人員賣出解釋：能否指導您的投資選擇？</li>
<li>MarketBeat 周評 - 7/1 - 7/5</li>
<li>投資中降級意味着什麼？</li>
<li>Constellation Brands 股票 2025 年第一季度：擊敗安海斯 - 布什？</li>
<li>複利利息如何計算？</li>
<li>高通股票在負面消息面前持續上漲</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJEWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=ARDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快速和最準確的報道。在發佈之前，該故事已經經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ Obama wins Presidential debate (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 奧巴馬贏得總統辯論（來自 Porter &amp; Company）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjAw" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8600&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Ardelyx right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 在 Ardelyx？</h2>
</div><p>Before you consider Ardelyx, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Ardelyx 之前，您可能想要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ardelyx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在購買的股票...而 Ardelyx 不在名單上。</p>
</div><p>While Ardelyx currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Ardelyx 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

HC Wainwright 上調了對 Ardelyx, Inc. (NASDAQ:ARDX) 的 2026 財年每股收益預期